Merit Medical

Q2 FY2026 EarningsQ2 FY26 exceeded consensus across all key metrics: revenue of $418.8M vs. $405.3M expected, and Non-GAAP EPS of $1.19 vs. $0.96. Organic constant currency revenue grew 9% YoY, driven by double-digit growth in OEM and Therapeutic segments. Management raised FY26 guidance, forecasting revenue of $1.631B–$1.643B and Non-GAAP EPS of $4.25–$4.35, both significantly above prior outlooks.